P04.04 - Targeting to Tumor-Associated Antigen ENO1 Provides Preventive and Therapeutic Effects on Disease Progression of Lung Cancer

Abstract

Listen

Translate article

We previously identified ENO1 as an immunogenic tumor-associated autoantigen which was overexpressed in 95% patients with non-small cell lung cancer (NSCLC). Its expression status is highly associated with the 5-year overall and progression-free survivals of the patients. In this study, we intended to disclose if the ENO1 immune responses were also correlated with the clinical outcomes of NSCLC patients and examined if re-stimulation of the responses might provide preventive and therapeutic immunities against cancers.